Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon Feb 14, 2023 05:20AM
Pfizer (PFE) Completes Acquisition of Global Blood Therapeutics (GBT) Oct 5, 2022 09:03AM
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022 Sep 15, 2022 06:00PM
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference Sep 8, 2022 08:00AM
Pfizer (PFE) to Acquire Global Blood Therapeutics (GBT) for $5.4 Billion, $68.50 Per Share Aug 8, 2022 06:46AM
View Older Stories

Aug 8, 2022 06:45AM Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 8, 2022 06:45AM Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 4, 2022 04:05PM GBT Announces New Employment Inducement Grants
Aug 3, 2022 04:05PM GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
Jul 29, 2022 08:00AM GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Jul 26, 2022 05:59AM Global Blood's (GBT) Oxbryta Granted Marketing Authorization in UK
Jul 26, 2022 03:01AM MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Jul 26, 2022 03:01AM MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Jul 14, 2022 08:00AM GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
Jul 13, 2022 08:00AM The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
Jul 7, 2022 04:05PM GBT Announces New Employment Inducement Grants
Jun 29, 2022 08:00AM GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Jun 16, 2022 08:00AM NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
Jun 13, 2022 08:00AM New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Jun 13, 2022 08:00AM New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Jun 10, 2022 05:34AM Global Blood Therapeutics (GBT) Reports New Real-World Evidence Data Supporting Clinical Use of Oxbryta in Sickle Cell Disease
Jun 10, 2022 03:00AM GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Jun 10, 2022 03:00AM GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Jun 6, 2022 10:00AM The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
Jun 6, 2022 08:05AM Global Blood Therapeutics (GBT) Granted FDA FDA Orphan Drug and Rare Pediatric Disease Designations for Inclacumab and GBT601
Jun 6, 2022 08:00AM GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Jun 2, 2022 04:05PM GBT Announces New Employment Inducement Grants
Jun 1, 2022 04:05PM GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
May 12, 2022 10:00AM GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
May 5, 2022 04:05PM GBT Announces Participation in Upcoming Investor Conferences
May 5, 2022 04:05PM GBT Announces New Employment Inducement Grants
May 4, 2022 04:05PM GBT Reports First Quarter 2022 Financial Results
Apr 28, 2022 08:20AM GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Apr 27, 2022 08:00AM GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
Apr 7, 2022 04:05PM GBT Announces New Employment Inducement Grants
Mar 24, 2022 04:05PM GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
Mar 10, 2022 04:05PM GBT Announces New Employment Inducement Grants
Mar 3, 2022 08:00AM The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
Feb 28, 2022 08:00AM GBT Announces Participation in Upcoming Investor Conferences
Feb 23, 2022 04:05PM GBT Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 16, 2022 04:05PM GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
Feb 16, 2022 06:01AM Global Blood Therapeutics (GBT) Announces European Approval of Oxbryta for Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Feb 16, 2022 06:00AM European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Feb 16, 2022 06:00AM European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Feb 3, 2022 08:00AM GBT Announces New Employment Inducement Grants
Jan 10, 2022 08:00AM Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
Jan 6, 2022 08:00AM GBT Announces New Employment Inducement Grants
Jan 4, 2022 08:00AM GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 17, 2021 02:07PM FDA Approves Global Blood's (GBT) Supplemental New Drug Application for Expanded Indication of Oxbryta for Children as Young as 4 Years of Age with Sickle Cell Disease
Dec 17, 2021 02:05PM U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
Dec 17, 2021 10:36AM Global Blood's (GBT) Oxbryta Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
Dec 17, 2021 10:33AM GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
Dec 17, 2021 10:33AM GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
Dec 13, 2021 09:01AM Global Blood Therapeutics (GBT) Reports Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers
Dec 13, 2021 09:00AM GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
View Older Stories